Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market
Trading on The NASDAQ Global Market is expected to commence on February 12, 2013. The Company's units and warrants will continue to trade on The NASDAQ Capital Market under the symbols “SGYPU” and “SGYPW,” respectively.
About Synergy Pharmaceuticals Inc.
Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy‘s lead proprietary drug candidate, plecanatide, is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a positive Phase I study of plecanatide in healthy volunteers, and positive Phase IIa and Phase IIb/III clinical trials in patients with chronic idiopathic constipation (CIC). Detailed positive findings from a recently completed Phase IIb/III clinical trial will be presented at a major scientific meeting this year. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), having initiated the first trial in IBS-C patients in late 2012. Synergy’s second GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel diseases, and has just completed its first Phase I trial in healthy volunteers. More information is available at http://www.synergypharma.com.
Website: http://www.synergypharma.com
Contact
Janet Skidmore
Office:+1 215-658-4915
Mobile: +1 215-429-2917
Send Email
Investor Contact:
Danielle Spangler
The Trout Group
Send Email
+1(646) 378-2924
This news is a press release provided by Synergy Pharmaceuticals.
-
2013년 5월 21일 23:00
-
2013년 5월 15일 09:52